

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

EQA round: TDM1/19 - Therapeutic Drugs

Dead line: 12.04.2019

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(83) Primidone					9							9	9	100%									0
— Samples and groups —	[µmol/L]																						
Sample B1		35,1	1,3	3,6	9		CVP	35,1	1,6	24%	26,6	43,6	9	9	100%								0
(999) another manufacturer		33,8	3,2	9,4	5	0							5										
Other					4	0							4										
							1x 60, 3x 118																
(84) Phenobarbital					27								27	26	96%								0
— Samples and groups —	[µmol/L]																						
Sample A1		57,0	4,8	8,4	27		CVP	57	2,2	20%	45,6	68,4	27	26	96%								0
(1) Abbott		59,0	3,8	6,5	11	0							11										
(60) Roche		56,2	2,5	4,4	9	0							9										
Other					7	0							7										
							2x 58, 1x 118, 2x 179, 2x 999																
Sample B1		160	11	6,8	27		CVP	160	5,2	20%	128	192	27	27	100%								0
(1) Abbott		166	8,4	5,0	11	0							11										
(60) Roche		152	4,6	3,0	9	0							9										
Other					7	0							7										
							2x 58, 1x 118, 2x 179, 2x 999																
(85) Phenytoin					48								48	47	98%								0
— Samples and groups —	[µmol/L]																						
Sample A1		50,8	3,1	6,1	48		CVP	50,8	1,1	20%	40,6	61	48	47	98%								0
(1) Abbott		51,6	4,2	8,2	17	0							17										
(60) Roche		50,6	2,1	4,2	15	0							15										
Other					16	0							16										
							1x 12, 3x 29, 3x 58, 2x 118, 1x 149, 3x 179, 3x 999																
Sample B1		61,4	3,6	5,9	48		CVP	61,4	1,3	20%	49,1	73,7	48	48	100%								0
(1) Abbott		61,7	4,1	6,7	17	0							17										
(60) Roche		61,7	3,0	4,8	15	0							15										
Other					16	0							16										
							1x 12, 3x 29, 3x 58, 2x 118, 1x 149, 3x 179, 3x 999																
(86) Carbamazepin					64								64	61	95%								0
— Samples and groups —	[µmol/L]																						
Sample A1		23,8	2,1	8,6	64		CVP	23,8	0,63	20%	19	28,6	64	61	95%								0
(1) Abbott		24,0	0,85	3,5	22	0							22										
(29) Siemens (DPC)		21,9	2,5	12	6	0							6										
(60) Roche		23,2	2,0	8,5	20	0							20										
Other					16	0							16										
							2x 12, 4x 58, 2x 118, 1x 149, 4x 179, 3x 999																
Sample B1		17,2	1,7	9,8	64		CVP	17,2	0,51	20%	13,7	20,7	64	62	97%								0
(1) Abbott		17,3	0,74	4,3	22	0							22										
(29) Siemens (DPC)		16,3	1,6	10	6	0							6										
(60) Roche		16,7	1,7	10	20	0							20										
Other					16	0							16										
							2x 12, 4x 58, 2x 118, 1x 149, 4x 179, 3x 999																
(87) Ethosuximide					8								8	7	88%								0
— Samples and groups —	[µmol/L]																						
Sample A1		458	31	6,8	8		CVP	458	24	24%	348	568	8	7	88%								0
(999) another manufacturer		461	27	5,8	5	0							5										

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

EQA round: TDM1/19 - Therapeutic Drugs

Dead line: 12.04.2019

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(87) Ethosuximide					8							8	7	88%									0
— Samples and groups —	[µmol/L]																						
Sample A1		458	31	6,8	8		CVP	458	24	24%	348	568	8	7	88%								0
Other					3	0							3										
							2x 118, 1x 179																
Sample B1		482	24	4,9	8		CVP	482	18	24%	366	598	8	8	100%								0
(999) another manufacturer		474	13	2,7	5	0							5										
Other					3	0							3										
							2x 118, 1x 179																
(88) Valproic acid					84								84	82	98%								0
— Samples and groups —	[µmol/L]																						
Sample A1		519	32	6,1	84		CVP	519	8,5	20%	415	623	84	83	99%								0
(1) Abbott		498	27	5,4	28	0							28										
(29) Siemens (DPC)		531	33	6,1	8	0							8										
(58) Beckman Coulter (Olympus)		563	39	7,0	8	0							8										
(60) Roche		519	24	4,6	29	0							29										
(179) Siemens (Bayer)		531	37	6,9	8	0							8										
Other					3	0							3										
							2x 12, 1x 149																
Sample B1		239	17	7,2	84		CVP	239	4,6	20%	191	287	84	83	99%								0
(1) Abbott		227	12	5,3	28	0							28										
(29) Siemens (DPC)		235	3,0	1,3	8	0							8										
(58) Beckman Coulter (Olympus)		254	16	6,2	8	0							8										
(60) Roche		242	12	5,1	29	0							29										
(179) Siemens (Bayer)		261	16	6,2	8	0							8										
Other					3	0							3										
							2x 12, 1x 149																
Set of samples 2																							
(89) Amicacin					30								30	25	83%								0
— Samples and groups —	[µmol/L]																						
Sample A2		6,42	0,92	14	30		CVP	6,42	0,41	20%	5,13	7,71	30	25	83%								0
(60) Roche		6,42	0,87	14	20	0							20										
Other					10	0							10										
							3x 1, 3x 12, 2x 58, 1x 149, 1x 166																
Sample B2		22,4	1,2	5,4	30		CVP	22,4	0,54	20%	17,9	26,9	30	28	93%								0
(60) Roche		22,4	1,4	6,4	20	0							20										
Other					10	0							10										
							3x 1, 3x 12, 2x 58, 1x 149, 1x 166																
(90) Gentamicin					59								59	54	92%								0
— Samples and groups —	[µmol/L]																						
Sample A2		28,3	5,2	18	59		CVP	28,3	1,7	31%	19,5	37,1	59	54	92%								0
(1) Abbott		29,0	1,9	6,7	25	0							25										
(60) Roche		24,7	5,3	22	22	0							22										
(179) Siemens (Bayer)		32,6	6,3	19	6	0							6										
Other					6	0							6										
							3x 12, 3x 58																
Sample B2		13,6	1,6	12	59		CVP	13,6	0,51	31%	9,38	17,9	59	59	100%								0
(1) Abbott		14,3	0,93	6,5	25	0							25										

